

AWARD NUMBER:

W81XWH-12-1-0474

TITLE:

"MICRORNAS TO PATHWAYS IN
PROSTATE CANCER PROGRESSION"

PRINCIPAL INVESTIGATOR:

DR. ROBERT BLELLOCH, MD, PHD.

CONTRACTING ORGANIZATION:

THE UNIVERSITY OF
CALIFORNIA, SAN FRANCISCO
San Francisco, CA 94103

REPORT DATE:

October 2014

TYPE OF REPORT:

ANNUAL

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2014		2. REPORT TYPE ANNUAL		3. DATES COVERED 30 th Sept,2013 – 29 th Sept,2014	
4. TITLE AND SUBTITLE MicroRNAs to Pathways in Prostate Cancer Progression				5a. CONTRACT NUMBER –	
				5b. GRANT NUMBER W81XWH-12-1-0474	
				5c. PROGRAM ELEMENT NUMBER –	
6. AUTHOR(S) Robert Blleloch, MD, PhD. E-Mail: BllelochR@stemcell.ucsf.edu				5d. PROJECT NUMBER –	
				5e. TASK NUMBER –	
				5f. WORK UNIT NUMBER –	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The University of California, San Francisco 1855 Folsom Street, Ste. 425 San Francisco, CA-94103				8. PERFORMING ORGANIZATION REPORT NUMBER –	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S) –	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)-	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The purpose of this Idea Development Award is to understand the molecular basis of early events in prostate cancer progression. In particular the proposal focuses on a class of non-coding RNAs called microRNAs that function to suppress large networks of genes during cell fate transitions. The proposal was based on preliminary data showing that in absence of all microRNAs, prostate tumors associated with PTEN loss fail to progress. The goal here is to determine the microRNAs and downstream-regulated pathways responsible for this striking block. In the past year we have isolated RNA from YFP-labeled prostates of the four genetic backgrounds (wild type, Dgcr8 knockout, PTEN knockout, and PTEN/Dgcr8 double knockout) and performed mRNA array analysis. Bioinformatic analysis of this data showed few changes likely secondary to poor correlation between reporter and loop out of PTEN and/or Dgcr8. We are currently testing alternative approaches for isolating mutant cells and performing miRNA and mRNA measurements with minimal RNA input to ensure improved homogeneity of cells evaluated.					
15. SUBJECT TERMS nothing listed					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 8	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction.....	4
2. Keywords.....	4
3. Accomplishments.....	4
4. Impact.....	5
5. Changes/Problems.....	6
6. Products.....	7
7. Participants & Other Collaborating Organizations.....	N/A
8. Special Reporting Requirements.....	N/A
9. Appendices.....	N/A

PROGRESS REPORT:

1. Introduction

The overall goal of this funded proposal is to dissect the molecular mechanisms of early tumor progression in the prostate. The proposed aims are based on preliminary findings showing that the loss of a specific class of regulatory molecules called microRNAs blocks progression from early hyperplasia to dysplasia in a PTEN knockout model of the disease. The aims themselves are to uncover the underlying microRNAs (aim 1) and microRNA regulated pathways (aim 2) that are normally responsible for progression. Knowing the miRNAs and downstream pathways that cooperate with PTEN loss (the most commonly deleted gene in prostate cancer) has the potential to improve the evaluation of the risk of early progression. The ability to distinguish and treat tumors that are likely to progress will have a broad impact on the disease as it would have the potential to diminish the overdiagnosis and overtreatment of early disease.

The goals for year two as outlined in the statement of work were to:

- 1) Profile RNA samples for miRNA and messenger RNA species (year one months 11-13)
- 2) Bioinformatics analysis and validation (month 14-16)
- 3) Building constructs (months 17-24)
- 4) Introduction of constructs into mice (months 22-30)

2. Keywords

Prostate Cancer, MicroRNAs, Post-transcriptional Regulation , Progression, Senescence, Basal and Luminal Cells, Transformation.

3. Accomplishments

Summary of Key Accomplishments

- 1) Development of mouse model that allows dissection of microRNA function during early stages of tumor development.
- 2) Development of methods to isolate and evaluate transformed cells from the otherwise heterogeneous cellular background of the prostate.
- 3) Preparation of high quality RNA from small numbers of cells allowing for future measurements of changes in mRNA and small RNA levels between different mutant backgrounds.
- 4) Improved sequencing strategies for measuring miRNAs from very small amounts of input RNA.

Our progress toward the aims of this proposal is as follows:


We have now evaluated earlier timepoints, identifying a suppression of progression by Dgcr8 loss even earlier than we previously suspected (i.e. at 12 weeks).

We performed array profiling for messenger RNAs from YFP-sorted cells from four mice of each genotype. YFP expression was driven by the probasin-cre transgene and therefore should label the cells that also had cre-mediated deletion of *Pten* and/or *DGCR8*. Unfortunately the arrays were not informative. As shown in Figure 1a, the samples clustered based on *PTEN*. However loss of *DGCR8* did not change the profile in a significant way. There were no significant expression changes between *PTEN* knockout prostates and *PTEN/Dgcr8* double knockout prostates. There are a number of explanations for this including that YFP is not a robust marker for cells in the mouse that have complete loop out of all floxed alleles.

We performed the profiling on 12 week old prostates. Histological analysis and immunophenotyping was performed on matching tissues from the same prostates. Immune staining for YFP expression was not uniform at this time point in all prostates.. However in the *Pten*^{KO} prostates, glands were uniformly hyperplastic suggesting that that *PTEN* was lost in most cells and thus there being a disconnect between YFP and *PTEN* losses. In the *Pten*^{KO}/*Dgcr8*^{KO} prostates showed some focal hyperplasia, which could also be explained by incomplete loop out of all alleles across cells. Another issue with the array data was that the dynamic range in signal was low as shown in Figure 1b, likely secondary to the extensive amplification required to get signal.

4.) Impact

Our studies to date demonstrate that there is a requirement for microRNAs for the histological progression of *PTEN*^{KO}-mediated prostate cancer. As early as 12 weeks there is a reduction in hyperplasia in the *PTEN/Dgcr8* double knockouts compared to *PTEN* knock-out and any further progression is entirely blocked. The block is associated with cell senescence thereby identifying a central role for miRNAs in promoting prostate cancer progression by overcoming this important barrier. As such it provides a targetable node in prostate cancer for treatment. We are now



searching for specific miRNAs that underlie this regulation with the ultimate goal of testing how delivery of the miRNAs and inhibitors to miRNAs can be used to manipulate this node. Such knowledge could lead to future drug treatments.

5.) Changes/Problems

As described under accomplishments, we have run into a number of problems with profiling the tumors including tissue heterogeneity, imperfect activation of our reporter relative to loop out of other alleles, and small amount of RNA we are able to purify from the tumors. We are working on a number of solutions as described below. We also suffered a setback when the mice stopped breeding and required rescue by out-crossing to the wild-type line. It took several months to rebuild homozygous lines.

Solutions to problems with reporter lines and limited RNA yield.

A.) Use whole prostates as input for profiling. A recent study suggests that expression profiling of whole prostates may reveal global differences in prostate expression[1]. We have revised tissue digestion methods that result in digestion with better cell viability, which will lead to higher quantity and quality of RNA. This strategy avoids the issue of trying to get pure tissues using the YFP marker in the different genetic backgrounds.

B.) FACS sort based on surface markers for prostate epithelial cells instead of using the YFP expression as a marker. The approach described in alternate plan A suffers from the heterogeneity of the whole tissue. Therefore, we are also testing sorting basal and luminal populations, from stromal cells. Our colleague, Davide Ruggero, has recently succeeded in using the markers CD49f and Sca-1 to do exactly this in the PTEN knockout model. He will help us set it up in our model. As probasin-cre is broadly active in the epithelium, this approach should give us mostly looped out cells.

C.) Develop new profiling methods that can use very low RNA input: In the realm of miRNA profiling, we have been working on novel methods to build libraries from very little input RNA (less than or equal to 1 ng) (Figure 2). This method will allow us to measure the miRNAs, even if we are unable to improve our yield of RNA material from the sorted prostates.

D.) Measure miRNAs in human prostate tissue and serum. Reviewers of this grant requested that we use human materials along with our mouse work. We have been hesitant to use cell lines as they are even more distant from the human disease than the mouse models. However, with our improved library techniques, we have been able to sequence miRNAs from small prostate biopsies and even serum. We have successfully isolated miRNAs from serum samples and used deep sequencing to measure relative miRNA levels (Figure 3). This provides an unbiased approach for screening for miRNAs relevant to human prostate cancer progression. We then propose to use the same bioinformatics approach as previously proposed to determine mRNA targets of these miRNAs. We can then utilize the mouse model to test the functionality of the miRNAs and their impact on mRNA expression pathways

on prostate cancer development and progression as described in part b of both aims.

6.) Products

We expect to submit our first manuscript this year describing the phenotype associated with microRNA loss in the Pten null prostate without profiling of mRNAs and miRNAs.

Reference

1. Zhang B, Chen H, Zhang L, Dakhova O, Zhang Y, et al. (2014) A dosage-dependent

pleiotropic role of Dicer in prostate cancer growth and metastasis. *Oncogene* 33: 3099–3108.
doi:10.1038/onc.2013.281.





Figure 3: MiRNA profile analysis of human serum. A.) Total RNA purified from cells is predominantly ribosomal. B.) However in serum the 22 nt miRNA species is the dominant form. C.) Sequencing of a serum library produces read lengths of the expected size. D.) Over 500 miRNA species are found in blood, although top 9 microRNAs make up over 50% of the pool.